EZH2 and colorectal carcinoma: In another study, EZH2 interacted with DNMT3a and was proven to contribute to oxaliplatin resistance in CRC by epigenetically silencing and inhibiting the expression of MEIS1 (Table 1) (Li et al., 2022).